title: [Pharmacological and clinical properties of ECARD combination tablets LD & HD, fixed-dose combination of candesartan cilexetil and hydrochlorothiazide].
authors.affiliation: Kusumoto_Keiji@takeda.co.jp
authors.forename: Keiji
authors.initials: K
authors.lastname: Kusumoto
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Mori
authors.forename: Junichi
authors.initials: J
authors.lastname: Tanokashira
authors.forename: Nobuo
authors.initials: N
authors.lastname: Totsuka
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D000818:Animals; D001562:Benzimidazoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D001713:Biphenyl Compounds / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D017326:Clinical Trials, Phase III as Topic; D004334:Drug Administration Schedule; D004338:Drug Combinations; D015195:Drug Design; D006801:Humans; D006852:Hydrochlorothiazide / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D006973:Hypertension / Q000188:drug therapy*; D011817:Rabbits; D051381:Rats; D049993:Sodium Chloride Symporter Inhibitors / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology; D013607:Tablets; D013777:Tetrazoles / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D004338:Drug Combinations; D049993:Sodium Chloride Symporter Inhibitors; D013607:Tablets; D013777:Tetrazoles; D006852:Hydrochlorothiazide; C077793:candesartan cilexetil